Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).

ABSTRACT:

Objectives

To summarize descriptively health-related quality of life (HRQOL) and physical activity (PA) evaluated with a mobile application and wearable device among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 -) advanced breast cancer (ABC) treated with first- or second-line palbociclib plus endocrine therapy (ET) or ET alone.

Methods

HRQOL was assessed with the EORTC QLQ-C30 at baseline and Day 15 of 6 treatment cycles (~ 24 weeks). PA metrics were averaged on a weekly basis for 24 weeks. Co-primary endpoints were mean change from baseline in Global Health Status (GHS) and sedentary time.

Results

Ninety-nine patients were enrolled; 78 received palbociclib plus ET (mean age: 57.2 years; 75.6% initiated first-l

SUBMITTER: Bando H 

PROVIDER: S-EPMC12394391 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature